|
|
|
|
Perfusion-based upstream production offers up to 24% lower cost and significantly higher productivity than fed-batch, enabling faster timelines, better facility utilization, and improved quality.
|
|
|
|
|
N-1 perfusion enables higher inoculum densities, faster production, and reduced costs without altering fed-batch processes. Explore a practical path to intensification for biologics manufacturers.
|
|
|
|
|
Perfusion cell culture technology supports high cell densities and product yields for viral vaccine manufacturing, offering a reliable way to produce high-quality cells at a commercial scale.
|
|
|
|
|
Discover how TFDF-based perfusion technology boosts lentiviral vector production by over 10-fold, slashes costs, and accelerates the commercialization of CAR-T and other advanced cell therapies.
|
|
|
|
|
Achieve consistent, large-scale buffer preparation efficiently. Learn about a scalable, single-use approach for high-volume 10x PBS formulation and its process efficiency benefits.
|
|
|
|
|
|
|
Streamline viral vector manufacturing with perfusion technologies that reduce costs and improve scalability. Find out how a tangential flow depth filtration system enhances yield and quality.
|
|
|
|
|
Continuous bioprocessing is revolutionizing biotherapeutic manufacturing. Gain expert insights about cutting-edge innovations in mAb production that enable scalable solutions for next-gen therapies.
|
|
|
|
|
|
|
